950140 — Englewood Lab Balance Sheet
0.000.00%
- KR₩245bn
- KR₩231bn
- $133.59m
- 70
- 60
- 88
- 88
Annual balance sheet for Englewood Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 9.46 | 7.51 | 8.78 | 13.9 | 26.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 20.8 | 30 | 28.7 | 54.9 | 44.2 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 63.2 | 74 | 74.9 | 102 | 99.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 35.7 | 31.6 | 30.3 | 28.5 | 30.1 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 99.9 | 108 | 107 | 135 | 136 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 28.5 | 23.5 | 27.7 | 39.8 | 30 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 44.2 | 39.8 | 33.4 | 45.5 | 38 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 55.8 | 68.3 | 73.4 | 89.1 | 97.9 |
| Total Liabilities & Shareholders' Equity | 99.9 | 108 | 107 | 135 | 136 |
| Total Common Shares Outstanding |